FINWIRES · TerminalLIVE
FINWIRES

$AVAH

10 stories mentioning AVAH

Every FINWIRES story that references AVAH, newest first.

Insider Trading

Aveanna Healthcare Holdings Insider Sold Shares Worth $43,680,000, According to a Recent SEC Filing

Robert M Williams Jr, 10% Owner, on June 03, 2026, sold 7,000,000 shares in Aveanna Healthcare Holdings (AVAH) for $43,680,000. Following the Form 4 filing with the SEC, Williams has control over a total of 33,065,892 common shares of the company, with 33,065,892 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1832332/000119312526258798/xslF345X05/ownership.xmlPrice: $6.68, Change: $+0.05, Percent Change: +0.75%

$AVAH
Insider Trading

Aveanna Healthcare Holdings Insider Sold Shares Worth $43,680,000, According to a Recent SEC Filing

Paul R Vigano, 10% Owner, on June 03, 2026, sold 7,000,000 shares in Aveanna Healthcare Holdings (AVAH) for $43,680,000. Following the Form 4 filing with the SEC, Vigano has control over a total of 33,065,892 common shares of the company, with 33,065,892 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1832332/000119312526258806/xslF345X05/ownership.xmlPrice: $6.67, Change: $+0.04, Percent Change: +0.53%

$AVAH
Wire

Aveanna Healthcare's Preferred Payor Relationships Buffer Medicaid Pressures, RBC Says

Aveanna Healthcare's (AVAH) growing market presence and steady improvement in preferred payor mix create a natural buffer against potential Medicaid budgetary pressures, RBC Capital Markets said Wednesday.The company's growing concentration of preferred payor clients shifts its volume toward managed care organizations that value and differentially reimburse private duty nursing services to reduce total healthcare spend, according to the note.RBC said it believes preferred payor relationships largely insulate Aveanna's PDN platform from state budget constraints, especially as payors seek to expand access to higher quality care in lower cost settings. The brokerage added that the recently completed Family First acquisition enhances the company's scale and market density.The company presents a strong value proposition for Medicaid managed care payors that seems to be underappreciated by the market, the brokerage said. The stock's recent pullback offers a compelling buying opportunity, it added.RBC upgraded Aveanna Healthcare to outperform from sector perform, while maintaining a price target of $10.Shares of Aveanna rose more than 6% in Wednesday trading.Price: $6.87, Change: $+0.40, Percent Change: +6.11%

$AVAH
Research

RBC Upgrades Aveanna Healthcare Holdings to Outperform From Sector Perform, Keeps $10 Price Target

Aveanna Healthcare Holdings (AVAH) has an average rating of overweight and mean price target of $10.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AVAH
Wire

Aveanna Healthcare Shares Rise After Stephens Upgrade

Aveanna Healthcare (AVAH) shares rose 4.1% on Friday after Stephens upgraded the stock to overweight from equalweight and adjusted its price target to $11 per share from $10.Trading volume stood at over 1.9 million shares compared with a daily average of more than 1.3 million.Price: $7.75, Change: $+0.31, Percent Change: +4.17%

$AVAH
Research

Stephens Upgrades Aveanna Healthcare to Overweight From Equalweight, Adjusts Price Target to $11 From $10

Aveanna Healthcare Holdings Inc (AVAH) has an average rating of overweight and mean price target of $9.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AVAH
Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally higher.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Prestige Consumer Healthcare's (PBH) officials said Thursday that weak eye care sales and a difficult consumer backdrop drove disappointing fiscal Q4 results at the consumer healthcare products company. Its shares were down past 11%.Biogen (BIIB) shares fell nearly 7% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 23%.Aveanna Healthcare (AVAH) shares jumped past 8% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.

$AVAH$BIIB$DOCS$PBH
Sectors

Sector Update: Healthcare Stocks Softer Thursday Afternoon

Healthcare stocks edged down Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) decreased 0.5%.In corporate news, Biogen (BIIB) shares fell nearly 6% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Prestige Consumer Healthcare (PBH) reported weaker-than-expected Q4 results and issued 2026 guidance below consensus, with the shortfall driven primarily by supply constraints in Clear Eyes and broader execution pressures, Oppenheimer said in a note. Oppenheimer downgraded the stock to perform from outperform and removed its $65 price target. Prestige shares slumped past 8%.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 24%.Aveanna Healthcare (AVAH) shares jumped 11% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.

$AVAH$BIIB$DOCS$PBH
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Thursday

Healthcare stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) declining by 0.1%.Aveanna Healthcare (AVAH) stock was up more than 9% after the company reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.Biogen (BIIB) shares were up more than 1% after the company said a phase 2 study evaluating diranersen in patients with early Alzheimer's disease did not meet its primary endpoint evaluating dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at week 76.MeiraGTx (MGTX) stock was down 1% after the company posted a wider Q1 adjusted loss as revenue fell during the period.

$AVAH$BIIB$IBB$MGTX$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% higher and the iShares Biotechnology ETF (IBB) marginally declining.Aveanna Healthcare (AVAH) stock was up nearly 8% after the company reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.

$AVAH